Last reviewed · How we verify
Montelukast (High FeNO group)
Montelukast (High FeNO group) is a Leukotriene receptor antagonist Small molecule drug developed by Hull University Teaching Hospitals NHS Trust. It is currently FDA-approved. Also known as: Montelukast.
Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction.
Montelukast is a leukotriene receptor antagonist used primarily for the treatment of asthma and allergic rhinitis. It is particularly effective in patients with high fractional exhaled nitric oxide (FeNO) levels, indicating significant eosinophilic airway inflammation. The drug works by blocking the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and increased mucus production. Despite its efficacy, montelukast has been associated with several side effects, including neuropsychiatric events, which have led to caution in its use. The drug is not approved by the FDA for any specific indication related to high FeNO levels, but it remains a valuable option for managing asthma in certain patient populations.
At a glance
| Generic name | Montelukast (High FeNO group) |
|---|---|
| Also known as | Montelukast |
| Sponsor | Hull University Teaching Hospitals NHS Trust |
| Drug class | Leukotriene receptor antagonist |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Leukotrienes are potent inflammatory mediators that cause bronchoconstriction, increased vascular permeability, and mucus secretion. By blocking the CysLT1 receptor, montelukast reduces these effects, leading to improved respiratory function.
Approved indications
Boxed warnings
- Neuropsychiatric events (e.g., agitation, aggressive behavior, depression, disorientation, hallucinations, insomnia, irritability, restlessness, suicidal thinking and behavior)
Common side effects
- Headache
- Pharyngitis
- Upper respiratory infection
- Abdominal pain
- Diarrhea
- Nasal congestion
- Dizziness
- Fatigue
Drug interactions
- Warfarin: Monitor INR due to potential for increased anticoagulant effect
- Phenytoin, carbamazepine, rifampin: May decrease montelukast plasma concentrations
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
| US5656654A |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast (High FeNO group) CI brief — competitive landscape report
- Montelukast (High FeNO group) updates RSS · CI watch RSS
- Hull University Teaching Hospitals NHS Trust portfolio CI
Frequently asked questions about Montelukast (High FeNO group)
What is Montelukast (High FeNO group)?
How does Montelukast (High FeNO group) work?
Who makes Montelukast (High FeNO group)?
Is Montelukast (High FeNO group) also known as anything else?
What drug class is Montelukast (High FeNO group) in?
What development phase is Montelukast (High FeNO group) in?
What are the side effects of Montelukast (High FeNO group)?
What does Montelukast (High FeNO group) target?
Related
- Drug class: All Leukotriene receptor antagonist drugs
- Target: All drugs targeting CysLT1 receptor
- Manufacturer: Hull University Teaching Hospitals NHS Trust — full pipeline
- Therapeutic area: All drugs in Respiratory
- Also known as: Montelukast
- Compare: Montelukast (High FeNO group) vs similar drugs
- Pricing: Montelukast (High FeNO group) cost, discount & access